Tag: 300-400

On September 4, 2003, Petereit, Hans-Ulrich; Meier, Christian; Gryczke, Andreas published a patent.Product Details of 86393-32-0 The title of the patent was Melt extrusion consisting of salts of active ingredients and (meth)acrylate copolymer. And the patent contained the following:

The invention relates to a method for producing active ingredient-containing granules or powders involving the following steps: (a) melting a mixture consisting of a pharmaceutically active ingredient and of a (meth)acrylate copolymer, which is comprised of 40-75 weight% of radically polymerized C1-4 alkyl esters of acrylic acid or of methacrylic acid and can be comprised of 25-60 weight% (meth)acrylate monomers having an anionic group in the alkyl radial; (b) extruding the mixture, and; (c) comminuting the extrudate to form a granule or powder. The inventive method is characterized in that the active ingredient is the salt of an alk. substance, and in that the pH value, which can be measured on the obtained powder or granule, is equal to or less than pH 7.0. The invention also relates to pharmaceutical dosage forms or precursors thereof, which can be produced using the inventive method. Thus a hot melt compound was prepared by coextruding 50 mass parts Verapamil HCl and 50 mass parts Eudragit L 100-55, then 160 g of the ground hot melt compound was mixed with 230 g lactose, 180 g Avicel PH 102, 30 g Explotab and 3 g magnesium stearate and pressed to tablets. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Product Details of 86393-32-0

The Article related to melt extrusion coextrusion salt drug methacrylate copolymer verapamil hydrochloride, Pharmaceuticals: Formulation and Compounding and other aspects.Product Details of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 31, 2017, Le, Tien Canh published a patent.Formula: C17H21ClFN3O4 The title of the patent was Dual-rate release formulation with high drug loading comprising anionic polysaccharide amino acid complex, and preparation thereof. And the patent contained the following:

The present document describes a pharmaceutical excipient composition comprising a functionalized anionic polysaccharide having carboxyl groups complexed with an amino acid-divalent cation complex, monolithic solid dosage forms for dual rate release of an active pharmaceutical ingredient, comprising the pharmaceutical excipient composition and active pharmaceutical ingredients, as well as processes for preparing the pharmaceutical excipient composition The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Formula: C17H21ClFN3O4

The Article related to anionic polysaccharide amino acid complex dual rate pharmaceutical excipient, Pharmaceuticals: Formulation and Compounding and other aspects.Formula: C17H21ClFN3O4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On July 24, 2019, Bonacucina, Giulia; Cespi, Marco; Casettari, Luca; Torregiani, Elisabetta; Logrippo, Serena; Palmieri, Giovanni Filippo; Perinelli, Diego Romano; Ganzetti, Roberta; Sestili, Matteo published a patent.Application of 86393-32-0 The title of the patent was Gel formulations containing water-soluble active ingredients for oral administration of drugs in patients with dysphagia. And the patent contained the following:

A pharmaceutical gel formulation is disclosed containing water soluble therapeutically active ingredient which are generally available only as oral solid dosage forms or tablets and/or capsules and/or immediate release powders or granules, which can be administered in the presence of abnormalities in the swallowing process. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Application of 86393-32-0

The Article related to formulation gel oral dysphagia tablet capsules powder granule pharmaceutical, Pharmaceuticals: Formulation and Compounding and other aspects.Application of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On July 17, 2001, Talwar, Naresh; Sen, Himadri; Staniforth, John N. published a patent.Related Products of 86393-32-0 The title of the patent was Orally administered controlled drug delivery system providing temporal and spatial control. And the patent contained the following:

A pharmaceutical composition in the form of tablets or capsules provides a combination of temporal and spatial control of drug delivery to a patient for effective therapeutic results. The pharmaceutical composition comprises a drug, a gas generating component, a swelling agent, a viscolyzing agent, and optionally a gel forming polymer. The swelling agent belongs to a class of compounds known as super-disintegrants (e.g., cross-linked polyvinylpyrrolidone or sodium CM-cellulose). The viscolyzing agent initially and the gel forming polymer thereafter form a hydrated gel matrix which entraps the gas, causing the tablet or capsule to be retained in the stomach or upper part of the small intestine (spatial control). At the same time, the hydrated gel matrix creates a tortuous diffusion path for the drug, resulting in sustained release of the drug (temporal control). A preferred once daily ciprofloxacin formulation comprises 69.9 ciprofloxacin base, 0.34 sodium alginate, 1.03 xanthan gum, 13.7 sodium bicarbonate, 12.1 cross-linked polyvinylpyrrolidone, and optionally other pharmaceutical excipients, the formulation being in the form of a coated or uncoated tablet or capsule. A tablet contained ranitidine hydrochloride (I) 300.00, xanthan gum (Keltrol TF) 20.00, sodium alginate (Keltone LVCR) 20.00, cross-linked CM-cellulose 50.00, sodium bicarbonate 50.00, magnesium stearate 5.00, and talc 5.00%. The % cumulative release of I from the tablets was 84.37% after 8 h. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Related Products of 86393-32-0

The Article related to oral controlled drug delivery system, ranitidine controlled release tablet, Pharmaceuticals: Formulation and Compounding and other aspects.Related Products of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 31, 2002, Wang, Jingkang; Liu, Yong; Yin, Qiuxiang published an article.Formula: C17H21ClFN3O4 The title of the article was Studies on the mechanism of primary nucleation of ciprofloxacin hydrochloride monohydrate. And the article contained the following:

A general expression for the relation between induction period and supersaturation was developed based on polynuclear approach. Different mechanism of primary nucleation in solution can be illustrated by the expression. The results of induction period determined by laser scattering method shows that the crystallization of ciprofloxacin hydrochloride monohydrate in water/ethanol or aqueous solution is by the mechanism of primary nucleation followed by one-dimensional diffusion growth, and then one-dimensional continuous or “birth and spread” growth on crystal face. The growth mechanism on the crystal face is affected by temperature and solvent. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Formula: C17H21ClFN3O4

The Article related to ciprofloxacin hydrochloride monohydrate primary nucleation mechanism, Unit Operations and Processes: Separation Processes and other aspects.Formula: C17H21ClFN3O4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On June 30, 1996, Linnhoff, G. Caldero; Vidal, R. Canals; Ges, J. M. Caldero published an article.Product Details of 86393-32-0 The title of the article was Spectrophotometric study of ciprofloxacin solutions in the presence of ferric ions in acid medium. And the article contained the following:

Spectrophotometric anal. of ciprofloxacin solutions depending on the pH has allowed the acidity constant Ka = (2.80 ± 0.2) × 10-7 (pKa = 6.55 ± 0.05) to be determined Spectrophotometric studies of ciprofloxacin solutions in the presence of ferric ions in acid medium has allowed the presence of a complex to be identified, the formula of the FeCip2+ itself to be established, by Job’s continuous variations method, and the dissociation constant K = (8.77 ± 0.92) × 10-10 (pK=9.06±0.05) to be calculated by two different methods: titration method and Bjerrum’s method of corresponding solutions The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Product Details of 86393-32-0

The Article related to spectrophotometry ciprofloxacin solution ferric chloride, Pharmaceutical Analysis: Natural Drug Materials and other aspects.Product Details of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On January 31, 1997, Schierholz, Joerg M.; Rump, Alexis; Pulverer, Gerhard published an article.Computed Properties of 86393-32-0 The title of the article was New antiinfectious biomaterials. Ciprofloxacin containing polyurethanes as potential drug delivery systems to prevent foreign-body infections. And the article contained the following:

Device related infections are an increasing problem since foreign materials are used in modern medicine. Ciprofloxacin-HCl salt (CAS 86393-32-0) and lipophilic ciprofloxacin-betaine (Bay o 9867) incorporated into polyurethanes by solvent casting technique were studied in order to develop antiinfectious properties of this biomaterial. Drug release rates, bacterial colonization and morphol. features of the polymer-ciprofloxacin combinations were studied and the physico-chem. mechanisms of the delivery were discussed. Ciprofloxacin salt showed a fast initial release rate, whereas ciprofloxacin-betaine was characterized by a more continuous release behavior. A higher diffusion of the lipophilic ciprofloxacin-betaine in the polymer could be shown as compared to its salt incorporated into the polyurethane. Bacterial colonization to the antibiotic-loaded polyurethanes was inhibited effectively only by preparations showing a slower but more sustained drug release. SEM demonstrated that the polyurethane-antibiotic combination was most homogeneous for ciprofloxacin-betaine. Polyurethane material loaded with ciprofloxacin salt showed crystals at the surface and a granular structure of the polymeric matrix. Crystalline structure of the drug on polymeric surfaces varied with loading concentration and lipophilicity. High homogeneity is required for a sustained and prolonged release and effective inhibition of bacterial colonization. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Computed Properties of 86393-32-0

The Article related to ciprofloxacin release polyurethane prosthetic, biomaterial polyurethane infection inhibition, Pharmaceuticals: Prosthetics and Medical Goods and other aspects.Computed Properties of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On May 15, 2021, Deng, Yanlin; Liu, Sylvia Yang; Chua, Song Lin; Khoo, Bee Luan published an article.Computed Properties of 86393-32-0 The title of the article was The effects of biofilms on tumor progression in a 3D cancer-biofilm microfluidic model. And the article contained the following:

Components within the tumor microenvironment, such as intratumoral bacteria (IB; within tumors), affect tumor progression. However, current exptl. models have not explored the effects of extratumoral bacteria (EB; outside tumors) on cancer progression. Here, we developed a microfluidic platform to analyze the influence of bacterial distribution on bladder cancer progression under defined conditions, using uropathogenic Escherichia coli. This was achieved by establishing coating (CT) and colonizing (CL) models to simulate the different invasion and colonization modes of IB and EB in tumor tissues. We demonstrated that both EB and IB induced closer cell-cell contacts within the tumor cluster, but cancer cell viability was reduced only in the presence of IB. Interestingly, cancer stem cell counts increased significantly in the presence of EB. These outcomes were due to the formation of extracellular DNA-based biofilms by EB. Triple therapy of DNase (anti-biofilm agent), ciprofloxacin (antibiotic), and doxorubicin (anti-cancer drug) could effectively eradicate biofilms and tumors simultaneously. Our preclin. proof-of-concept provides insights on how bacteria can influence tumor progression and facilitate future research on anti-biofilm cancer management therapies. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Computed Properties of 86393-32-0

The Article related to cancer progression biofilm microfluidic model, antibacterial agents, biofilms, combinatorial therapy, drug screening, microfluidic tumor models, Mammalian Pathological Biochemistry: Oncology and other aspects.Computed Properties of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On June 10, 2018, Shetty, Nivedita; Park, Heejun; Zemlyanov, Dmitry; Mangal, Sharad; Bhujbal, Sonal; Zhou, Qi published an article.Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate The title of the article was Influence of excipients on physical and aerosolization stability of spray dried high-dose powder formulations for inhalation. And the article contained the following:

The aim of this study is to investigate the influence of excipients on phys. and aerosolization stability of spray dried Ciprofloxacin dry powder inhaler formulations. The model drug, Ciprofloxacin hydrochloride, was co-spray dried with excipients such as disaccharides (sucrose, lactose, trehalose), mannitol and L-leucine. The spray dried samples were stored at two different relative humidity (RH) conditions of: (1) 20% and (2) 55% RH at 20°C. Ciprofloxacin co-spray dried with disaccharides and L-leucine in the mass ratio of 1:1 demonstrated an increase in fine particle fraction (FPF) as compared with the spray dried Ciprofloxacin alone when stored at 20% RH. However, deterioration in FPF of Ciprofloxacin co-spray dried with disaccharide and mannitol was observed upon storage at 55% RH as compared to the corresponding formulations stored at 20% RH due to particle agglomeration. Whereas, 10% and 50% weight/weight L-leucine in the formulation showed no change in aerosol performance (FPF of 71.1±3.5% and 79.5±3.1%, resp.) when stored at 55% RH for 10 days as compared to 20% RH (FPF of 68.1±0.3% and 73.6±7.1%, resp.). L-Leucine demonstrated aerosolization stability by alleviating crystallization of Ciprofloxacin to some extent and preventing significant change in particle morphol. L-Leucine is well-recognized as aerosolization enhancer; our study has shown L-leucine is also a phys. and aerosolization stabilizer for spray dried Ciprofloxacin DPI formulations. Such stability enhancing activities were attributed to the enrichment of L-leucine on the particle surface as confirmed by XPS data, and intermol. interactions between L-leucine and Ciprofloxacin as measured by FT-IR. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

The Article related to excipient aerosolization spray drying powder formulation inhalation, antibiotics, dry powder inhaler (dpi), excipients, fine particle fraction (fpf), spray drying, Pharmaceuticals: Formulation and Compounding and other aspects.Safety of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On September 4, 2018, Shetty, Nivedita; Ahn, Patricia; Park, Heejun; Bhujbal, Sonal; Zemlyanov, Dmitry; Cavallaro, Alex; Mangal, Sharad; Li, Jian; Zhou, Qi Tony published an article.Related Products of 86393-32-0 The title of the article was Improved Physical Stability and Aerosolization of Inhalable Amorphous Ciprofloxacin Powder Formulations by Incorporating Synergistic Colistin. And the article contained the following:

This study aimed to develop dry powder inhaler (DPI) combination formulations of ciprofloxacin and colistin for use in respiratory infections. Effects of colistin on phys. stability and aerosolization of spray-dried ciprofloxacin were examined The combination DPI formulations were produced by co-spray drying colistin and ciprofloxacin in mass ratios of 1:1, 1:3, and 1:9. Colistin and ciprofloxacin were also co-sprayed with L-leucine in the mass ratio of 1:1:1. The phys. and aerosolization stability of the selected co-sprayed formulations stored at 20, 55, and 75% relative humidity (RH) were examined Formulation characterizations were carried out using powder X-ray diffraction (PXRD) for crystallinity, SEM for morphol. and particle size distribution, and dynamic vapor sorption for moisture sorption. Particle surface anal. was performed using XPS, energy dispersive X-ray spectrometry, and nano-time-of-flight secondary ion mass spectrometry. Potential intermol. interactions were studied using Fourier-transform IR spectroscopy (FTIR). Aerosol performance was evaluated using a multistage liquid impinger with a RS01 monodose inhaler device. PXRD diffractograms showed that the co-spray-dried colistin-ciprofloxacin formulation in the mass ratio (1:1) was amorphous at 55% RH for up to 60 days; whereas the co-spray-dried colistin-ciprofloxacin (1:3) and colistin-ciprofloxacin (1:9) crystallized after storage for 3 days at 55% RH. However, the extent of crystallization for the combination formulations was less as compared to the spray-dried ciprofloxacin alone formulation. Surface morphol. of the co-spray-dried formulations at different concentrations did not change even after storage at 55% RH for 60 days, unlike the spray-dried ciprofloxacin alone powder which became rougher after 3 days of storage at 55% RH. Surface anal. data indicated surface enrichment of colistin in the co-spray-dried formulations. Increasing colistin concentration on the composite particles surfaces improved aerosol performance of ciprofloxacin. FTIR data demonstrated intermol. interactions between colistin and ciprofloxacin, thereby delaying and/or preventing crystallization of ciprofloxacin when co-spray-dried. Co-spray drying ciprofloxacin with colistin in the mass ratio (1:1) completely prevented crystallization of ciprofloxacin at 55% RH for up to 60 days. However, the colistin-ciprofloxacin formulation (1:1) began to fuse when stored at 75% RH due to moisture absorption resulting in a compromised aerosol performance. In contrast, the colistin-ciprofloxacin-leucine (1:1:1) formulation demonstrated no particle fusion, enabling a stable aerosol performance at 75% RH for 7 days. This study demonstrated that incorporation of colistin in the spray-dried formulations can improve phys. stability and aerosolization of amorphous ciprofloxacin at 55% RH. At 75% RH, further addition of L-leucine in the formulation prevented particle fusion and deterioration in aerosol performance, attributed to the enrichment of nonhygroscopic L-leucine on the particle surface. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Related Products of 86393-32-0

The Article related to stability inhalant ciprofloxacin colistin powder synergy, aerosol performance, co-spray drying, dry powder inhaler, multidrug resistance, storage humidity, Pharmaceuticals: Formulation and Compounding and other aspects.Related Products of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics